Send to

Choose Destination
J Clin Psychiatry. 2005 Feb;66(2):228-30.

Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.

Author information

Department of Psychiatry, University Medical Center Utrecht, The Rudolf Magnus Institute of Neuroscience, Utrecht, the Netherlands.



In the present study, we examined the efficacy of bupropion for patients with obsessive-compulsive disorder (OCD).


Twelve patients with OCD according to DSM-IV criteria were included in an open trial with bupropion, maximum dosage 300 mg per day, during 8 weeks. The primary efficacy parameter was the Yale-Brown Obsessive Compulsive Scale (YBOCS). A responder was defined by a reduction in score on the YBOCS of > or = 25%. Data were collected from February 2003 to July 2003.


An intent-to-treat analysis using the last observation carried forward demonstrated that bupropion had no mean effect on OCD symptoms (mean YBOCS decrease was 1.1 +/- 9.6). Four patients improved, with a mean decrease on the YBOCS of 31%, and 2 of them met responder rate criteria. Eight patients experienced an exacerbation of OCD symptoms, with a mean increase on the YBOCS of 21%.


Bupropion is not an effective treatment for OCD, but the bimodal distribution of the effect supports the notion that dopamine might be involved in the pathophysiology of OCD.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Physicians Postgraduate Press, Inc.
Loading ...
Support Center